Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
X8yrnVb8Y7ZMdG5u
Listen
